

Effectiveness of Digital Breast Tomosynthesis Compared With Digital Mammography Outcomes Analysis from 3 Years of Breast Cancer Screening

McDonald ES, Oustimov A, Weinstein SP, Synnestvedt MB, Schnall M, Conant EF

JAMA Oncology, Published online February 18, 2016. doi:10.1001/jamaoncol.2015.5536

Objective

A new study of breast cancer screening published online by JAMA Oncology suggests digital breast tomosynthesis (DBT) outcomes were sustainable with significant reduction in patient recall, increasing cancer cases per recalled patients and a decline in interval cancers.

Materials and Methods

A total of 44,468 screening examinations with 23,958 patients over a four year time period. The study began on September 1, 2010 and concluded on September 30, 2014 (excluding September 2011, which was the transition period from DM to DBT). Differences in screening outcomes between each DBT year and the DM year, as well as between groups of women with only 1, 2, or 3 DBT screenings, were assessed, and the odds of recall adjusted for age, race/ethnicity, breast density, and prior mammograms were estimated. Data analysis was performed between February 16 and October 26, 2015.

Findings

Recall rates rose slightly for years 1 to 3 of DBT (88, 90, and 92 per 1000 screened, respectively) but remained significantly reduced compared with the DMO rate of 104 per 1000 screened. Reported as odds ratios (95% CIs), the findings were DM vs DBT1, 0.83; DM vs DBT2, 0.85 and DM vs DBT3, 0.87. The cancer cases per recalled patients continued to rise from DMO rate of 4.4% to 6.2%, 6.5% and 6.7% for years 1 to 3 of DBT, respectively. Outcomes assessed for the most recent screening for individual women undergoing only 1, 2, or 3 DBT screenings during the study period demonstrated decreasing recall rates of 130, 78, and 59 per 1000 screened, respectively. Interval cancer rates, determined using available follow-up data, decreased from 0.7 per 1000 women screened with the use of DM to 0.5 per 1000 screened with the use of DBT1.

Conclusion

Digital breast tomosynthesis screening outcomes are sustainable, with significant recall reduction, increasing cancer cases per recalled patients, and a decline in interval cancers.

hologic.com | info@hologic.com | +1.781.999.7300

MED-00190 Rev.002 (9/16) © 2016 Hologic, Inc. All rights reserved. Printed in USA. Specifications are subject to change without prior notice. Hologic is a trademarks and/or registered trademarks of Hologic and/or Hologic subsidiaries in the United States and/or other countries. All other trademarks and registered trademarks are the property of their respective owners. This information is intended for medical professionals in the U.S. and other markets and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your local Hologic representative or write to womenshealth@hologic.com.